Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis | Zendy

Jeffrey A. Cohen | Zendy; An. Belova | Zendy; Krzysztof Selmaj | Zendy; Christian Wolf | Zendy; Maria Pia Sormani | Zendy; Janine Oberyé | Zendy; Evelyn van den Tweel | Zendy; R. J. Mulder | Zendy; N.P. Koper | Zendy; Gerrit Voortman | Zendy; Frederik Barkhof | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis

Author(s) -

Jeffrey A. Cohen,

An. Belova,

Krzysztof Selmaj,

Christian Wolf,

Maria Pia Sormani,

Janine Oberyé,

Evelyn van den Tweel,

R. J. Mulder,

N.P. Koper,

Gerrit Voortman,

Frederik Barkhof

Publication year - 2015

Publication title -

jama neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.298

H-Index - 231

eISSN - 2168-6157

pISSN - 2168-6149

DOI - 10.1001/jamaneurol.2015.2154

Subject(s) - glatiramer acetate , tolerability , medicine , placebo , multiple sclerosis , randomized controlled trial , adverse effect , magnetic resonance imaging , clinical endpoint , clinical trial , surgery , radiology , pathology , psychiatry , alternative medicine

The patents for the first approved treatments for relapsing-remitting multiple sclerosis are expiring, creating the opportunity to develop generic alternatives.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research